174 related articles for article (PubMed ID: 10334546)
1. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
[TBL] [Abstract][Full Text] [Related]
2. The bioavailability of oral fludarabine phosphate is unaffected by food.
Oscier D; Orchard JA; Culligan D; Cunningham D; Johnson S; Parker A; Klein M; Gieschen H
Hematol J; 2001; 2(5):316-21. PubMed ID: 11920267
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Lichtman SM; Etcubanas E; Budman DR; Eisenberg P; Zervos G; D'Amico P; O'Mara V; Musgrave K; Cascella P; Melikian A; Hinderling PH; Ferrer JM; Williams GJ
Cancer Invest; 2002; 20(7-8):904-13. PubMed ID: 12449721
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J
Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
Ogawa Y; Hotta T; Tobinai K; Watanabe T; Sasaki Y; Minami H; Morishima Y; Ogura M; Seriu T
Ann Oncol; 2006 Feb; 17(2):330-3. PubMed ID: 16275653
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
[TBL] [Abstract][Full Text] [Related]
7. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
[TBL] [Abstract][Full Text] [Related]
8. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
10. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M
J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569
[TBL] [Abstract][Full Text] [Related]
11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
13. [The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
Gershanovich ML; Zaritskiĭ AIu; Medvedeva NV; Abdulkadyrov KM; Samuskevich IG; Beresneva IA
Vopr Onkol; 1998; 44(6):696-700. PubMed ID: 10087967
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
16. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
Puccio CA; Mittelman A; Lichtman SM; Silver RT; Budman DR; Ahmed T; Feldman EJ; Coleman M; Arnold PM; Arlin ZA
J Clin Oncol; 1991 Sep; 9(9):1562-9. PubMed ID: 1714949
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
Decaudin D; Bosq J; Tertian G; Nedellec G; Bennaceur A; Venuat AM; Bayle C; Carde P; Bendahmane B; Hayat M; Munck JN
J Clin Oncol; 1998 Feb; 16(2):579-83. PubMed ID: 9469344
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
Tobinai K; Watanabe T; Ogura M; Morishima Y; Ogawa Y; Ishizawa K; Minami H; Utsunomiya A; Taniwaki M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Seriu T; Hotta T
J Clin Oncol; 2006 Jan; 24(1):174-80. PubMed ID: 16330664
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
